GigaMune
Developing in-vivo cell therapies for cancer and inherited blood disorders using T-cell receptor technology.
Website: https://www.gigamune.com/
Cover Block
Publicly reported
The first read on GigaMune is straightforward: this is a small, early-stage cell therapy company with a public profile shaped more by research positioning and grant support than by commercial disclosure [Crunchbase, retrieved 2024] [PRWeb, Sep 2018]. The available record points to a San Francisco company founded in 2017, now presenting itself around in-vivo cell therapy built on T-cell receptor work [Crunchbase, retrieved 2024] [gigamune.com, retrieved 2024].
| Field | Value |
|---|---|
| Name | GigaMune |
| Tagline | Developing in-vivo cell therapies for cancer and inherited blood disorders using T-cell receptor technology [gigamune.com, retrieved 2024] |
| Headquarters | San Francisco, USA [Crunchbase, retrieved 2024] |
| Founded | 2017 [Crunchbase, retrieved 2024] |
| Stage | Seed [Crunchbase, retrieved 2024] |
| Business model | B2B |
| Industry | Deeptech |
| Technology type | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2) [gigamune.com, retrieved 2024] |
| Funding label | Seed |
| Total disclosed funding | ~$1.1M, from a $300,000 NCI grant in September 2018 and an $800,000 NCI project grant in September 2025; other disclosed financings were undisclosed in amount [PRWeb, Sep 2018] [GovTribe, Sep 2025] [PRWeb, Apr 2019] [CB Insights, Mar 2023] |
Links
Publicly reported
- Website: https://www.gigamune.com/
Summary and Signal
PUBLIC GigaMune is a San Francisco biotech startup developing T-cell receptor discovery tools and in vivo cell-therapy approaches, and it merits attention because its public record shows a real scientific pivot from ex vivo TCR discovery toward in vivo CAR-T delivery, backed by National Cancer Institute grant support and a small but continuing financing history [gigamune.com] [GenomeWeb, Apr 2020] [GovTribe, Sep 2025]. The company was founded in 2017 and was described in 2020 as a spinout from GigaGen, with early work centered on finding rare tumor-reactive TCRs from patient immune repertoires for cancer applications [PRWeb, Apr 2020].
The product story is the main point of interest. Earlier materials position GigaMune around TCR capture and engineering for solid-tumor targets, while current company materials emphasize delivering genetic instructions directly into patients' T cells to create multiple-dose in vivo CAR-T therapies, a shift that could matter if it translates into more scalable manufacturing and dosing than conventional autologous cell therapy, though public clinical evidence is not yet available in the cited material [BioSpace, Feb 2022] [gigamune.com].
The founding team appears scientifically credible on paper, if still thinly documented through independent reporting. Public materials identify David Johnson, Ph.D., MBA, as co-founder and CEO with an immune genomics background, and Matthew Spindler, Ph.D., as co-founder and research lead; Spindler also led the company's 2018 NCI grant work and was identified as lead author on its Nature Biotechnology study announcement [PRWeb, Jul 2018] [PRWeb, Sep 2018] [PRWeb, Apr 2020].
On financing, the public record points to a grant-led capital base rather than a heavily syndicated venture round. Confirmed disclosures include a $300,000 NCI SBIR grant in September 2018, an undisclosed angel financing announced in April 2019, an undisclosed seed financing surfaced by CB Insights in March 2023, and an $800,000 federal grant in September 2025, for roughly $1.1 million in disclosed non-undisclosed funding [PRWeb, Sep 2018] [PRWeb, Apr 2019] [CB Insights, Mar 2023] [GovTribe, Sep 2025].
The commercial picture remains early. GenomeWeb reported that GigaMune had no revenues or partnerships on the books as of April 2020, although a 2022 partnership announcement with Champions Oncology indicates subsequent external validation of the underlying TCR discovery platform; over the next 12 to 18 months, the most important watchpoints are whether the company can convert platform claims into repeatable pharma relationships, publish more preclinical evidence for its in vivo delivery approach, and show that its strategic repositioning is more than website language [GenomeWeb, Apr 2020] [BioSpace, Feb 2022] [gigamune.com].
No independent source found -- This section relies materially on company materials and PR-driven coverage, with partial corroboration from GenomeWeb, BioSpace, CB Insights, and GovTribe.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed approximately $1.1M |
Company Overview
PUBLIC GigaMune is a San Francisco biotechnology company founded in 2017, focused on T-cell receptor discovery and in-vivo cell-therapy technologies for cancer and inherited blood disorders [Crunchbase] [gigamune.com]. Public company materials indicate the business began around TCR discovery and has since shifted its front-door positioning toward delivering genetic instructions directly into patients' T cells for what it describes as multiple-dose in-vivo CAR-T therapies [gigamune.com]. The available public record supports the headquarters, founding year, and broad platform description, but not a fuller legal-entity history beyond the company profiles now online [Crunchbase] [gigamune.com].
The milestone trail is relatively compact, which is common for a seed-stage therapeutic platform still closer to technical validation than commercial scale. Crunchbase records the company as founded in 2017 [Crunchbase], while the website reflects the current disease focus and platform framing [gigamune.com]. Later public profiles also point to an expanded therapeutic scope that includes autoimmune applications alongside oncology and inherited blood disorders, suggesting the platform thesis has widened over time rather than staying fixed on a single cancer program [Crunchbase] [gigamune.com].
One source, partially checked -- Based on company website and Crunchbase only, with core facts partially corroborated but several operating details still dependent on company-controlled materials.
The Product and the Stack
Core platform
MIXED The technical story is more interesting than the company’s current scale suggests. GigaMune began by positioning itself around T cell receptor discovery, specifically a platform intended to identify rare, tumor-reactive TCRs from patient immune repertoires faster than conventional screening [gigamune.com] [PRWeb, April 2020]. External coverage aligns with that framing: GenomeWeb reported in April 2020 that the company planned to develop TCR profiling for pharmaceutical customers, while BioSpace described GigaMune in 2022 as capturing and engineering TCRs directed against solid-tumor targets for cancer cell therapy [GenomeWeb, April 2020] [BioSpace, February 2022].
The present-day positioning appears broader, and somewhat shifted. On its website, GigaMune emphasizes delivering genetic instructions directly into patients’ T cells to create what it calls multiple-dose in vivo CAR-T therapies for cancer and inherited blood disorders [gigamune.com]. SBIR materials also describe a technical base that uses microfluidics, genomics, and mammalian display to generate natively paired TCR repertoire libraries for engineered TCR-Treg therapies, which suggests the platform may span both oncology and immune-modulation applications rather than a single product path [SBIR.gov].
Evidence of product maturity
MIXED Public evidence supports scientific activity and collaborations, but not a mature commercial product. In July 2018, GigaMune announced a collaboration with Massachusetts General Hospital focused on using its TCR discovery technology to identify therapeutic receptors from healthy-donor samples, and in February 2022 Champions Oncology announced a co-development partnership to discover novel tumor-reactive TCRs [PRWeb, July 2018] [BioSpace, February 2022]. That said, GenomeWeb reported in April 2020 that the company had no revenues or partnerships on the books at that time, which places at least part of the current product narrative in the category of platform ambition rather than demonstrated market adoption [GenomeWeb, April 2020].
The main analytical caution is that most detailed performance claims remain company-originated. Statements about lentivectors built for in vivo cell therapy and preclinical efficacy in mouse lymphoma models appear on founder or company-controlled profiles rather than in the independent reporting captured here [LinkedIn] [gigamune.com]. For public-market style diligence, the next proof points would be peer-reviewed preclinical data tied to the newer in vivo delivery thesis, and clearer evidence that the company’s discovery platform has translated into repeatable external programs rather than one-off research collaborations [PRWeb, April 2020] [BioSpace, February 2022].
No independent source found -- This section relies materially on company website claims and company-originated announcements, with partial support from GenomeWeb and BioSpace for the earlier TCR discovery platform.
The Market They Are Entering
Publicly reported
The commercial backdrop matters because GigaMune sits at the intersection of cell therapy, gene delivery, and T-cell receptor discovery, three areas where scientific progress has continued even as financing has become more selective, and that usually shifts buyer attention toward platforms with a clearer route to differentiated biology or more manufacturable delivery models [GenomeWeb, Apr 2020] [BioSpace, Feb 2022]. Public source support for a precise TAM, SAM, or SOM is thin in the retrieved record, so the market lens here has to be built from adjacent, named markets rather than from a company-specific sizing claim. That is a limitation, but it still gives a reasonable frame for where demand may emerge if the platform matures.
The nearest addressable markets suggested by the public record are not one single category. They are, first, TCR discovery and profiling services for pharmaceutical customers, which GenomeWeb reported the company planned to pursue in 2020 [GenomeWeb, Apr 2020]. They are, second, therapeutic programs built around tumor-reactive TCRs and in-vivo cell therapy, which appear in the company website, PRWeb releases, and the Champions Oncology partnership announcement [gigamune.com] [PRWeb, Apr 2020] [BioSpace, Feb 2022]. They are, third, a possible expansion into autoimmune applications through engineered TCR-Treg work, which appears in Crunchbase and SBIR-related materials, though those sources are less independently corroborated than the oncology narrative [Crunchbase] [SBIR.gov].
That produces a market picture with two different buyer types. One is the biopharma customer that may pay for discovery, profiling, or partnered R&D. The other is the eventual therapeutic market, where value creation would depend on moving from platform claims to clinical assets. GenomeWeb's reporting that GigaMune had no revenue or partnerships on the books in April 2020 is useful here because it marks how early the commercialization posture was at that point, while the 2022 Champions Oncology partnership indicates later external demand for the underlying discovery capability [GenomeWeb, Apr 2020] [BioSpace, Feb 2022].
| Market lens | Relevance to GigaMune | Public evidence |
|---|---|---|
| TCR discovery and profiling services (analogous market) | Closest near-term commercial surface if the company sells tools, screens, or partnered discovery work to pharma | GenomeWeb reported plans to develop TCR profiling for pharmaceutical customers [GenomeWeb, Apr 2020] |
| Tumor-reactive TCR therapeutics (adjacent market) | Matches the company's original focus on identifying and engineering rare tumor-reactive receptors for cancer cell therapy | PRWeb described the Nature Biotechnology results around TCR discovery, and BioSpace described work on solid-tumor-directed TCRs [PRWeb, Apr 2020] [BioSpace, Feb 2022] |
| In-vivo CAR-T and gene delivery (substitute or expansion market) | Aligns with the company's more recent positioning around delivering genetic instructions directly into patients' T cells | Company website positions the platform as multiple-dose in-vivo CAR-T [gigamune.com] |
| Autoimmune TCR-Treg therapies (expansion market) | Suggests a broader application set beyond oncology, but evidence is less mature and less independently verified | Crunchbase and SBIR-related materials reference TCR-Treg programs, including Type 1 Diabetes [Crunchbase] [SBIR.gov] |
The table points to a market definition that is broader than a single product category. The opportunity is most legible where discovery services and partnered research can act as an entry point, because that is the part of the market that requires the least clinical de-risking relative to a fully owned therapeutic program [GenomeWeb, Apr 2020] [BioSpace, Feb 2022].
Demand drivers in the public record are mostly scientific and operational rather than macroeconomic. The original value proposition was speed and sensitivity in finding rare, tumor-reactive TCRs from patient immune repertoires, which matters because target identification remains a bottleneck in solid-tumor cell therapy programs [PRWeb, Apr 2020] [BioSpace, Feb 2022]. The newer in-vivo positioning matters for a different reason: it attempts to address one of the best-known constraints in autologous cell therapy, namely manufacturing complexity outside the body, by moving the genetic engineering step into the patient instead [gigamune.com]. That does not establish feasibility or regulatory success, but it does align the company with a real problem set that has kept strategic interest high across the broader cell therapy ecosystem.
Adjacent and substitute markets are equally important because GigaMune is unlikely to compete in isolation. Ex vivo CAR-T, TCR-T, gene-editing-enabled cell therapies, and immune profiling platforms can all absorb budget that might otherwise flow to a TCR discovery or in-vivo delivery platform. The public evidence also shows some category drift over time, from oncology-focused TCR discovery toward in-vivo CAR-T and possibly autoimmune Treg applications, which can be read two ways: either as a sign of platform breadth or as an indication that the company is still searching for the most commercially durable wedge [PRWeb, Apr 2020] [gigamune.com] [Crunchbase].
Regulatory and macro forces cut both for and against the category. On the positive side, federal non-dilutive support from the National Cancer Institute in 2018 and again in 2025 indicates that parts of the underlying science fit existing public funding priorities in oncology and translational cell therapy [PRWeb, Sep 2018] [GovTribe, Sep 2025]. On the harder side, any move from discovery platform into therapeutic development places the company inside a long, capital-intensive path shaped by preclinical reproducibility, vector safety, CMC scale-up, and clinical regulation. The market can therefore be attractive in strategic value before it is attractive in revenue terms, which is typical for early platform biotechs but worth stating plainly here given the sparse public evidence of commercial traction.
One source, partially checked -- Market framing relies on one independent trade report and one independent partnership announcement, with several product-positioning claims supported mainly by company materials and database entries [GenomeWeb, Apr 2020] [BioSpace, Feb 2022] [gigamune.com] [Crunchbase].
The Competitive Field
Competitive map
MIXED GigaMune appears to sit in a narrow but shifting lane, between TCR discovery platforms for oncology and the newer in vivo cell-therapy thesis that aims to modify immune cells directly inside the patient rather than through ex vivo manufacturing [gigamune.com] [GenomeWeb, April 2020] [BioSpace, February 2022].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| GigaMune | Developing T-cell receptor discovery and in vivo cell-therapy technologies for cancer and inherited blood disorders | Seed, disclosed funding of about $1.1M across two NCI grants plus undisclosed angel and seed financings | Public materials show a pivot from rare tumor-reactive TCR discovery toward multiple-dose in vivo CAR-T, which could reduce ex vivo manufacturing burden if the approach translates clinically | [gigamune.com] [PRWeb, September 2018] [PRWeb, April 2019] [CB Insights, March 2023] [GovTribe, September 2025] |
| GigaGen | Scientific origin point for GigaMune, according to public reporting | Stage and funding not established in the provided public record | GigaMune was reported as a spinout from GigaGen, which suggests overlapping technical lineage and prior exposure to antibody and immune-repertoire work | [PRWeb, April 2020] |
| Revitope | Named competitor in the structured research | Stage and funding not established in the provided public record | Public record in the provided materials identifies it as a comparator, but does not support a narrower feature-level distinction | [Crunchbase, retrieved 2024] |
| Epitor Therapeutics | Named competitor in the structured research | Stage and funding not established in the provided public record | Public record in the provided materials identifies it as a comparator, but does not support a narrower feature-level distinction | [Crunchbase, retrieved 2024] |
The table is thin because the public record here is thin. That matters in itself. Among named players supported by the provided sources, only GigaMune has enough product detail to place precisely, and even then the company spans two adjacent categories: TCR identification for oncology programs and in vivo delivery of genetic payloads to T cells [GenomeWeb, April 2020] [gigamune.com] [BioSpace, February 2022].
The segment map therefore needs to be drawn from where GigaMune has actually shown its hand. In the earlier segment, the company looked like a discovery supplier, using repertoire screening to identify rare tumor-reactive TCRs and planning TCR profiling for pharma customers [GenomeWeb, April 2020] [PRWeb, April 2020]. In the newer segment, it is presenting itself as an in vivo CAR-T builder, which shifts the competitive set away from pure discovery tools and toward any company trying to bypass individualized ex vivo manufacturing with direct delivery approaches [gigamune.com]. GigaGen sits closest in technical lineage because GigaMune was reported as a spinout, while Revitope and Epitor Therapeutics are relevant named challengers in the structured record even though the supplied public sources do not give enough detail to map their exact modality overlap [PRWeb, April 2020] [Crunchbase, retrieved 2024].
GigaMune's clearest edge today is not scale or commercial reach, because the public record does not show either. The stronger case is scientific continuity. The company has raised non-dilutive NCI funding in both 2018 and 2025, published platform-related work highlighted by PRWeb in 2020, and secured named collaborations with Massachusetts General Hospital in 2018 and Champions Oncology in 2022 [PRWeb, July 2018] [PRWeb, September 2018] [PRWeb, April 2020] [BioSpace, February 2022] [GovTribe, September 2025]. That is a meaningful signal that the program has persisted across several years and technical iterations. Still, the durability of that edge looks perishable rather than locked in. Grant support validates scientific interest, but it does not establish product-market fit, and the company had no revenue or partnerships on the books as of April 2020, which suggests the commercial motion was still formative well after founding [GenomeWeb, April 2020].
The main exposure is execution against better-positioned categories. If GigaMune remains partly a discovery platform, then a company with an already-established pharma services channel would hold an advantage, because the evidence here does not show GigaMune owning that distribution path [GenomeWeb, April 2020]. If it leans fully into in vivo CAR-T, the bar becomes even higher: the company has to prove targeted delivery, repeat dosing, and safety well enough to stand apart from any adjacent in vivo cell-therapy effort, while doing so on a comparatively small disclosed capital base of roughly $1.1 million from the two public NCI awards, plus undisclosed private financing [PRWeb, September 2018] [GovTribe, September 2025] [PRWeb, April 2019] [CB Insights, March 2023]. GigaGen is the most concrete named comparator with a specific structural advantage in this record, because shared lineage implies the closest benchmark for talent and technical credibility, whereas Revitope and Epitor Therapeutics are named but not well enough described in the supplied sources to support a stronger claim [PRWeb, April 2020] [Crunchbase, retrieved 2024].
The most plausible 18-month scenario is a sorting event by proof point rather than by narrative. Winner if X: GigaMune, if it can convert the in vivo cell-therapy positioning into externally visible preclinical or partnership evidence that shows direct delivery is more than a repositioning of the earlier TCR discovery story [gigamune.com] [BioSpace, February 2022]. Loser if Y: GigaMune, if the company remains caught between service-style TCR profiling and therapeutics development without showing which business it can prosecute faster, because that would leave room for lineage-adjacent players such as GigaGen and other better-capitalized modality specialists to define the category terms first [GenomeWeb, April 2020] [PRWeb, April 2020].
Thinly sourced -- Core positioning is corroborated by company materials and independent trade coverage, but competitor-specific detail for Revitope and Epitor Therapeutics is only lightly supported in the provided public record, and several competitive inferences rest on sparse public evidence.
Opportunity
Upside case
PUBLIC The prize here is unusually large for a company of GigaMune's size because, if its platform works clinically and commercially, it is not selling a single therapy so much as a new delivery model for cell therapy, one that could move engineered T cells from bespoke ex vivo manufacturing toward repeat-dose treatment delivered inside the patient [gigamune.com] [BioSpace, Feb 2022].
The headline opportunity is to become a platform supplier for in vivo T-cell engineering, first in oncology and potentially later in adjacent immune indications. That outcome is still early, but it is not untethered from evidence. Public materials show a progression from a narrower TCR-discovery thesis toward a broader in vivo cell-therapy positioning, with the company now emphasizing direct delivery of genetic instructions into patients' T cells and earlier work centered on identifying tumor-reactive TCRs from immune repertoires [gigamune.com] [PRWeb, Apr 2020]. The supporting record is modest rather than broad, but there are signs of external validation: a 2018 National Cancer Institute grant, a later 2025 NCI project grant, and a 2022 partnership with Champions Oncology around tumor-reactive TCR discovery [PRWeb, Sep 2018] [GovTribe, Sep 2025] [BioSpace, Feb 2022]. For a pre-scale biotech, that combination does not prove product-market fit, but it does suggest the science has been legible enough to attract grant reviewers and an industry collaborator.
The most credible paths to scale are easier to see as distinct scenarios than as one linear plan.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Oncology platform partner | GigaMune becomes a specialist discovery and delivery partner for biopharma groups that want tumor-reactive TCR assets or in vivo cell-engineering capabilities without building the stack internally | A follow-on partnership after Champions Oncology, or conversion of discovery work into a deeper co-development program [BioSpace, Feb 2022] | The company has already announced one oncology partnership and has positioned TCR profiling and discovery as a service for pharma customers [BioSpace, Feb 2022] [GenomeWeb, Apr 2020] |
| In vivo CAR-T wedge | The company's current in vivo CAR-T positioning matures into a differentiated delivery platform that can support multiple-dose treatment rather than one-off manufactured cell products | Preclinical and grant-backed progress on lentivector delivery, especially under the 2025 NCI award targeting in vivo TCR delivery for stage-IV melanoma [gigamune.com] [GovTribe, Sep 2025] | Public sources show the company has shifted toward direct in vivo delivery and has secured grant funding tied to that thesis [gigamune.com] [GovTribe, Sep 2025] |
| Immune-program expansion | GigaMune uses its TCR and repertoire-engineering base to expand beyond oncology into immune modulation programs such as TCR-Treg therapies | Translation of SBIR-linked autoimmune work into a partnerable platform or indication-specific pipeline [Crunchbase, retrieved 2024] [SBIR.gov] | The public record is mixed but directionally consistent that the underlying technology can be applied beyond solid-tumor targeting into Treg-oriented programs [Crunchbase, retrieved 2024] [SBIR.gov] |
What compounding looks like here is technical and commercial at the same time. If GigaMune can show that its discovery engine reliably finds useful receptors and that its delivery system can place those instructions into T cells in vivo, each additional dataset should make target selection, construct design, and partner conversations easier. The early version of that flywheel is visible in the sequence of public milestones: foundational TCR-discovery work, a Nature Biotechnology-linked platform update discussed in 2020, then a 2022 oncology partnership, then a 2025 grant tied to in vivo delivery [PRWeb, Apr 2020] [BioSpace, Feb 2022] [GovTribe, Sep 2025]. That is not yet a network effect in the software sense, but it is the beginning of a platform-learning loop if the company can keep generating translational evidence.
The size of the win depends on which model GigaMune becomes. If it remains a discovery boutique, the upside is meaningful but bounded by research-services economics. If it becomes a platform owner in in vivo cell therapy, the comparable frame shifts toward venture-scale therapeutics infrastructure rather than contract research. Public materials here do not provide a defensible market-size figure or a directly usable public-comp set, so any valuation translation should stay conditional. Under the oncology platform partner or in vivo CAR-T wedge scenarios, a plausible bull case is a strategic-value outcome attached to platform optionality across multiple programs rather than a single asset, which could support venture-scale enterprise value well above the roughly $1.1 million in disclosed funding to date (scenario, not a forecast) [PRWeb, Sep 2018] [GovTribe, Sep 2025]. The gap between today's evidence and that upside is wide, but the reason the opportunity matters is simple: solving delivery and repeat dosing in cell therapy would expand the addressable market far beyond what a small receptor-discovery company could reach on its own [gigamune.com] [GenomeWeb, Apr 2020].
Thinly sourced -- Section relies on a mix of public company materials, grant records, and limited third-party coverage. Several core product-positioning claims remain company-described rather than independently corroborated.
Sources
Publicly reported
[Crunchbase, retrieved 2024] GigaMune - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/gigamune-inc
[PRWeb, Sep 2018] GigaMune wins grant from National Cancer Institute to develop cell therapy based on tumor-infiltrating lymphocytes | https://www.prweb.com/releases/gigamune_wins_grant_from_national_cancer_institute_to_develop_cell_therapy_based_on_tumor_infiltrating_lymphocytes/prweb15743648.htm
[gigamune.com, retrieved 2024] GigaMune | https://www.gigamune.com/
[GovTribe, Sep 2025] Federal Grant Award: Project Grant R44CA310160 | https://govtribe.com/award/federal-grant-award/project-grant-r44ca310160
[CB Insights, Mar 2023] GigaMune - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/gigamune
[GenomeWeb, Apr 2020] GigaMune Hopes to Offer TCR Screens to Pharmas While Scrambling to Keep Expression Libraries Alive | https://www.genomeweb.com/sequencing/gigamune-hopes-offer-tcr-screens-pharmas-while-scrambling-keep-expression-libraries-alive
[PRWeb, Apr 2020] GigaMune publishes results in Nature Biotechnology describing T-cell receptor discovery technology | https://www.prweb.com/releases/gigamune_publishes_results_in_nature_biotechnology_describing_t_cell_receptor_discovery_technology/prweb16990952.htm
[BioSpace, Feb 2022] Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors | https://www.biospace.com/champions-oncology-announces-a-partnership-with-gigamune-to-discover-novel-tumor-reactive-t-cell-receptors
[PRWeb, Jul 2018] GigaMune Secures Collaboration with Mass General for Development of Cell Therapies for Cancer | https://www.prweb.com/releases/GigaMune_Secures_Collaboration_with_Mass_General_for_Development_of_Cell_Therapies_for_Cancer/prweb15642764.htm
[PRWeb, Apr 2019] GigaMune closes angel financing to advance anti-tumor T cell receptor programs | https://www.prweb.com/releases/gigamune_closes_angel_financing_to_advance_anti_tumor_t_cell_receptor_programs/prweb16269382.htm
Articles about GigaMune
- GigaMune's Lentivectors Cleared Tumors in 100% of Mice — The San Francisco biotech has pivoted from a TCR screening service to a more ambitious bet on in-vivo gene delivery, backed by over $1 million in non-dilutive funding.